Congressional approval for President Donald Trump's revised North American Free Trade Agreement may hinge on a small provision that governs patent protections for drugmakers, according to The New York Times.
Pharmacy
After a two-year legal battle, Dr. Reddy's Laboratories has won the right to sell a cheaper version of a best-selling opioid addiction treatment in the U.S., according to Bloomberg.
Executives from five major pharmacy benefit managers have agreed to testify at a Senate Finance Committee hearing on high drug costs in April, according to The Hill.
Kentucky Attorney General Andy Beshear is investigating allegations that pharmacy benefit managers overcharged state health insurers for drugs and discriminated against independent pharmacies, Reuters reports.
Roche has sued more than a dozen former executives at Alliance Medical Holdings over what the drugmaker calls fraudulent schemes involving its diabetes test strips, according to Reuters.
Advertisement
A Florida pharmacist was sentenced to 10 years in prison this week for his role in a $121 million compounding pharmacy fraud scheme, the U.S. Justice Department announced.
The FDA will allow some manufacturers to sell blood pressure medications containing a probable cancer-causing impurity in a temporary effort to mitigate a shortage, according to Reuters.
In the last two months several pharma giants announced or completed deals to expand their portfolio of gene therapy treatments.
A former senior U.S. Drug Enforcement Administration official is now a paid adviser to OxyContin maker Purdue Pharma, which is facing numerous lawsuits for its alleged role in fueling the opioid epidemic, according to NBC News.
Catalyst Pharmaceuticals CEO told investors that its rare-disease drug is doing "better than expected" amid public outrage over the $375,000 price tag, according to a STAT news report.